Robin C. Kramer serves as Executive Vice President and Chief Financial Officer of Biogen Inc., a global biotechnology leader pioneering therapies for neurological and neurodegenerative diseases. In this role, Robin directs all aspects of the company's financial strategy, including capital allocation, financial planning and analysis, treasury operations, tax compliance, and investor relations. Robin's leadership ensures Biogen's robust financial position, enabling sustained investment in research and development while navigating complex regulatory and market dynamics in the biotech sector. With more than 25 years of finance experience in life sciences, Robin began their career at PricewaterhouseCoopers (PwC), rising to partner and leading audits for major pharmaceutical clients. Prior to joining Biogen in 2018, Robin held progressive roles at Shire plc as Vice President of Global Finance, where they orchestrated the financial aspects of the company's $32 billion acquisition by Takeda, and at Alexion Pharmaceuticals as Senior Vice President and CFO, driving revenue growth from $1.5 billion to over $4 billion through strategic partnerships and product expansions. Robin earned a Bachelor of Science in Accounting from the Wharton School of the University of Pennsylvania and an MBA from Harvard Business School, and is a Certified Public Accountant. Key achievements at Biogen include implementing a multiyear efficiency program that delivered $1.2 billion in cost savings, optimizing the capital structure to fund pipeline advancements like the ALS therapy Qalsody, and enhancing ESG reporting to attract impact investors. Under Robin's stewardship, Biogen has achieved consistent double-digit EPS growth, solidifying its position as a financial powerhouse in biotechnology.